Relubin Dosage/Direction for Use

No dose adjustments are required for renal insufficiency. lf moderate or severe neurotoxicity develops, RELUBIN should be discontinued. The dosage should be adjusted according to hematologic toxicity or hepatic insufficiency, whichever results in the lower dose.
Dose modifications for Hematologic Toxicity: Granulocyte counts should be ≥ 1,500 cells/mm³ prior to the administration of RELUBIN. Adjustments in the dosage of RELUBIN should be based on granulocyte counts obtained on the day of treatment according to Table 1 as follows: see Table 1.


Click on icon to see table/diagram/image


Note: For patients during treatment with RELUBIN who have experienced fever and/or sepsis while granulocytopenia or had 2 consecutive weekly doses held due to granulocytopenia, subsequent doses of RELUBIN should be: 22.5 mg/m², for granulocytes >1,500 cells/mm³.
Dose modification for Hepatic lnsufficiency: RELUBIN should be administered with caution to patients with hepatic insufficiency. ln patients who develop hyperbilirubinemia during treatment with RELUBIN, the dose should be adjusted for total bilirubin according to Table 2 as follows: see Table 2.


Click on icon to see table/diagram/image


Dose modification for concurrent hematological toxicity and hepatic insufficiency: In patients with both hematological toxicity and hepatic insufficiency, the lower of the doses determined from Table 1 and 2 should be administered.
Administration: Strictly by intravenous administration after appropriate dilution. The use of intrathecal route is contraindicated. It is recommended to infuse RELUBIN over 6-10 minutes after dilution in 20-50 mL of normal saline solution or 5% Dextrose solution. Administration should always be followed with at least 250 mL of an isotonic solution infusion to flush the vein.
In monotherapy, the usual dose given is 25-30 mg/m² once weekly.
ln combination chemotherapy the dose may be the same while the frequency of administration reduced, i.e.: day 1 and 5 every 3 week or day 1 and 8 every 3 weeks according to treatment protocol.